ASH 2021 | The RELEVANCE study: lenalidomide plus rituximab vs. rituximab-chemotherapy in the treatment of FL
Loretta Nastoupil
• 12 Dec 2021
In this video, Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, briefly highlights findings from the RELEVANCE study (NCT01650701), which compared lenalidomide plus rituximab versus rituximab-chemotherapy in patients with previously untreated follicular lymphoma. Although the results of this study were negative, Dr Nastoupil mentions the importance of further investigating chemotherapy-free options for patients with follicular lymphoma, and that the results from this study provide valuable information. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
